Zealand Pharma A/S
CSE:ZEAL
Zealand Pharma A/S
Interest Income Expense
Zealand Pharma A/S
Interest Income Expense Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Interest Income Expense
kr195.6m
|
CAGR 3-Years
118%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
69%
|
|
|
Genmab A/S
CSE:GMAB
|
Interest Income Expense
kr2.5B
|
CAGR 3-Years
37%
|
CAGR 5-Years
62%
|
CAGR 10-Years
54%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Interest Income Expense
-€67.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Interest Income Expense
kr75.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
13%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Interest Income Expense
-kr1.2m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Saniona AB
STO:SANION
|
Interest Income Expense
-kr27.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Zealand Pharma A/S
Glance View
Zealand Pharma A/S is a Danish biotechnology company that has carved a niche in the medical field by focusing on the design and development of innovative peptide-based medicines. Established in 1998 and headquartered in Copenhagen, the company is driven by a singular mission: to improve patients' lives through impactful treatments. Zealand's expertise lies in peptide therapeutics, a compelling segment of biopharmaceuticals due to their ability to mimic biological processes with high specificity and efficacy. The company has a keen focus on addressing unmet medical needs, particularly in the treatment of metabolic and gastrointestinal diseases. With a robust pipeline that ranges from early-stage research to late-stage clinical trials, Zealand Pharma leverages its proprietary technology to discover and develop novel pharmaceuticals that can be game-changers in their respective therapeutic areas. Zealand Pharma's business model centers around the development and commercialization of its proprietary medicines, both independently and through strategic partnerships. By collaborating with larger pharmaceutical companies, Zealand enhances its global commercialization capabilities and mitigates the financial risks inherent in drug development. For instance, the company has partnered with multinational corporations, allowing it to tap into resources for advanced research, regulatory processes, and worldwide distribution systems. Revenue streams are diversified through milestone payments, royalties, and direct sales, ensuring a steady inflow of cash that supports continued innovation. This strategic approach not only sustains its operations but also propels its mission of delivering transformative healthcare solutions. In essence, Zealand Pharma thrives at the confluence of science and strategy, driving both its financial health and its contributions to the biopharmaceutical landscape.
See Also
What is Zealand Pharma A/S's Interest Income Expense?
Interest Income Expense
195.6m
DKK
Based on the financial report for Dec 31, 2024, Zealand Pharma A/S's Interest Income Expense amounts to 195.6m DKK.
What is Zealand Pharma A/S's Interest Income Expense growth rate?
Interest Income Expense CAGR 10Y
69%
Over the last year, the Interest Income Expense growth was 953%. The average annual Interest Income Expense growth rates for Zealand Pharma A/S have been 118% over the past three years , and 69% over the past ten years .
You don't have any saved screeners yet